ID   KM20
AC   CVCL_L095
SY   KM-20
DR   BioSample; SAMN06481114
DR   cancercelllines; CVCL_L095
DR   GEO; GSM1448074
DR   KCLB; 80017
DR   Wikidata; Q54900064
RX   PubMed=2846163;
RX   PubMed=12060639;
RX   PubMed=25926053;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a HT-29 derivative (ICLAC; an early sample of KM20 had been tested by the core facility where the cell line was established and the STR profile corresponds to that of HT-29).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00513.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: KCLB; 80017; probable.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D21S11: 29,30
ST   D5S818: 11,12
ST   D7S820: 10
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 21
//
RX   PubMed=2846163;
RA   Morikawa K., Walker S.M., Nakajima M., Pathak S., Jessup J.M.,
RA   Fidler I.J.;
RT   "Influence of organ environment on the growth, selection, and
RT   metastasis of human colon carcinoma cells in nude mice.";
RL   Cancer Res. 48:6863-6871(1988).
//
RX   PubMed=12060639;
RA   Wang Q.-D., Li N., Wang X.-F., Kim M.M., Evers B.M.;
RT   "Augmentation of sodium butyrate-induced apoptosis by
RT   phosphatidylinositol 3'-kinase inhibition in the KM20 human colon
RT   cancer cell line.";
RL   Clin. Cancer Res. 8:1940-1947(2002).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//